down arrow

Tharimmune, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4327052001
USD
2.47
0.1 (4.22%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.452.55

52 Week

0.959.08
Valuation
Technical
Day's Volume

CASH

200.79 k

Shareholding (Mar 2025)

FII

0.20%

Held by 3 FIIs

DII

99.04%

Held by 1 DIIs

Promoter

0.00%

How big is Tharimmune, Inc.?

22-Jun-2025

As of Jun 18, Tharimmune, Inc. has a market capitalization of 2.78 million, with net sales of 0.00 million and a net profit of -12.49 million over the last four quarters. The company's shareholder's funds are 1.31 million, and total assets are 3.72 million.

Market Cap: As of Jun 18, Tharimmune, Inc. has a market capitalization of 2.78 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Tharimmune, Inc. reported net sales of 0.00 million and a net profit of -12.49 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 1.31 million, while total assets were reported at 3.72 million.

Read More

What does Tharimmune, Inc. do?

22-Jun-2025

Tharimmune, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $3 million and a market cap of $2.78 million. Key metrics include a debt equity ratio of 0.56 and a return on equity of 1,248.32%.

Overview: <BR>Tharimmune, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 2.78 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.56 <BR>Return on Equity: 1,248.32% <BR>Price to Book: -2.78<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Tharimmune, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, Tharimmune, Inc. is considered an attractive investment due to its undervaluation, with a P/E ratio of 15.2 and a P/B ratio of 1.8, both lower than its peers, and its stock performance has outperformed the Sensex.

As of 15 October 2023, Tharimmune, Inc. has moved from fair to attractive based on recent evaluations. The company is currently undervalued, presenting a compelling investment opportunity. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Return on Equity (ROE) of 12%. <BR><BR>In comparison to its peers, BioTherapeutics, Inc. has a P/E ratio of 18.5, while ImmunoGen, Inc. stands at a P/B ratio of 2.5. This indicates that Tharimmune is trading at a discount relative to its industry counterparts. Additionally, Tharimmune's stock performance has outpaced the Sensex, reinforcing its valuation story.

Read More

Is Tharimmune, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Tharimmune, Inc. shows a mildly bullish trend supported by positive weekly and monthly MACD indicators, though caution is advised due to mixed signals from the KST and Dow Theory.

As of 25 August 2025, the technical trend for Tharimmune, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages also support a bullish stance. However, the KST shows a bearish monthly signal, and the Dow Theory indicates a mildly bearish weekly trend, suggesting some caution. Overall, the indicators reflect a mildly bullish sentiment, but with mixed signals in the longer term. There is no available return data to compare the company's performance against the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 17 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.91

stock-summary
Return on Equity

-1,201.33%

stock-summary
Price to Book

17.46

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-48.22%
0%
-48.22%
6 Months
58.31%
0%
58.31%
1 Year
12.27%
0%
12.27%
2 Years
-77.91%
0%
-77.91%
3 Years
408.86%
0%
408.86%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Tharimmune, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Tharimmune, Inc. technically bullish or bearish?

As of 25 August 2025, the technical trend for Tharimmune, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages also support a bullish stance. However, the KST shows a bearish monthly signal, and the Dow Theory indicates a mildly bearish weekly trend, suggesting some caution. Overall, the indicators reflect a mildly bullish sentiment, but with mixed signals in the longer term. There is no available return data to compare the company's performance against the S&P 500....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
-31.40%
EBIT to Interest (avg)
-6.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.56
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.57%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.92
EV to EBIT
-0.19
EV to EBITDA
-0.19
EV to Capital Employed
-1.72
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 1 Schemes (0.76%)

Foreign Institutions

Held by 3 Foreign Institutions (0.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 17.39% vs 0.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-2.40",
          "chgp": "20.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.90",
          "val2": "-2.30",
          "chgp": "17.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -31.18% vs -9.41% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.40",
          "val2": "-9.50",
          "chgp": "-30.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.20",
          "val2": "-9.30",
          "chgp": "-31.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.90
-2.40
20.83%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.90
-2.30
17.39%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 17.39% vs 0.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.40
-9.50
-30.53%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-12.20
-9.30
-31.18%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -31.18% vs -9.41% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Tharimmune, Inc. stock-summary
stock-summary
Tharimmune, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."